Empirical evidence suggests that sitagliptin might improve steatosis by suppressing lipogenic and gluconeogenic pathways through the inhibitation of DPP-4 and increasing levels of biological activity of GLP-1 and GIP (48, 49). The gene discussed is GIP; the disease is steatosis.